Transaction Information
Capital Raise
SEK 60 million
February 2026
Financial Adviser
About BiBBInstruments AB
BiBBInstruments AB is a cancer diagnostics company that develops and manufactures EndoDrill®, a patented product line of electric-driven endoscopic biopsy instruments. EndoDrill® enables tissue sampling with high precision and quality, with the aim of improving the diagnosis of several serious cancers, including those of the stomach, pancreas, liver, lungs, and bladder. BiBB's product portfolio targets the global market for ultrasound-guided endoscopic (EUS/EBUS) biopsy instruments - the most advanced and fastest-growing segment of endoscopy.
In 2023, BiBB's lead product EndoDrill® GI received 510(k) clearance from the U.S. FDA. In early 2024, CE marking was obtained under the new MDR regulatory framework for all three product variants: EndoDrill® GI, EndoDrill® EBUS, and EndoDrill® URO. As a result, EndoDrill® became the first market-cleared electric-driven endoscopic biopsy system in both the U.S. and Europe.
The US launch of EndoDrill® GI began in the fall of 2025 in collaboration with TaeWoong Medical USA. EndoDrill® consists of sterile, single-use instruments paired with a dedicated drive system. BiBB was founded in 2013 by Dr. Charles Walther - cancer researcher at Lund University and senior consultant in clinical pathology at Skåne University Hospital
The net proceeds from the Share Issue:
Website: https://bibbinstruments.com/en/
SEK 60m Capital Raise
Q1 2026
NOK 50m Capital Raise
Q4 2025
SEK 29m Capital Raise
Q4 2025
SEK 123m Capital Raise
Q4 2025
SEK 36m Block Trade
Q3 2025
SEK 152m Capital Raise
Q3 2025
SEK 100m Capital Raise
Q3 2025
SEK 207m Public Offer (Fairness Opinion)
Q3 2025
SEK 350m Capital Raise (Senior Secured Bonds)
Q2 2025
SEK 17.5m Capital Raise
Q2 2025
SEK 30m Capital Raise
Q2 2025
SEK 50m Capital Raise
Q2 2025